Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.
Saved in:
| Title: | Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. |
|---|---|
| Authors: | Assoumou L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France lambert.assoumou@iplesp.upmc.fr., Baldé R; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France., Katlama C; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, service des maladies infectieuses, Paris, France., Abbar B; Sorbonne University, Department of Medical Oncology Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France., Delobel P; CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, INSERM, UMR1291, Université Toulouse III-Paul Sabatier, Toulouse, France., Allegre T; Department of Hematology Oncology & Internal Médicine Centre Hospitalier d'Aix en Provence, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France., Lavole A; GRC#04 Theranoscan, Département de Pneumologie et Oncologie Thoracique, AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France., Makinson A; INSERM U1175, Département de Maladies Infectieuses, Centre Hospitalier Universitaire de Montpellier, Université de Montpellier, Montpellier, France., Zaegel-Faucher O; Aix-Marseille Université, APHM Sainte-Marguerite, Service d'immuno-hématologie Clinique, Marseille, France., Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France., Soulie C; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, laboratoire de virologie, Paris, France., Veyri M; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département d'Oncologie Médicale, Paris, France., Bertheau M; Inserm-ANRS MIE, clinical research department, Paris, France., Algarte Genin M; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France., Gibowski S; Inserm-ANRS MIE, safety department, Paris, France., Marcelin AG; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, laboratoire de virologie, Paris, France., Bihan K; Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France., Baron M; Sorbonne University, Department of Medical Oncology Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France., Costagliola D; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France., Lambotte O; Département d'Immunologie Clinique, AP-HP, Hôpital Bicêtre, Université Paris-Saclay, Le Kremlin Bicêtre, France., Spano JP; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département d'Oncologie Médicale, Paris, France. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Aug 22; Vol. 12 (8). Date of Electronic Publication: 2024 Aug 22. |
| Publication Type: | Journal Article; Observational Study; Multicenter Study |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39179255 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Assoumou+L%22">Assoumou L</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France lambert.assoumou@iplesp.upmc.fr.<br /><searchLink fieldCode="AU" term="%22Baldé+R%22">Baldé R</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.<br /><searchLink fieldCode="AU" term="%22Katlama+C%22">Katlama C</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, service des maladies infectieuses, Paris, France.<br /><searchLink fieldCode="AU" term="%22Abbar+B%22">Abbar B</searchLink>; Sorbonne University, Department of Medical Oncology Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.<br /><searchLink fieldCode="AU" term="%22Delobel+P%22">Delobel P</searchLink>; CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, INSERM, UMR1291, Université Toulouse III-Paul Sabatier, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Allegre+T%22">Allegre T</searchLink>; Department of Hematology Oncology & Internal Médicine Centre Hospitalier d'Aix en Provence, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France.<br /><searchLink fieldCode="AU" term="%22Lavole+A%22">Lavole A</searchLink>; GRC#04 Theranoscan, Département de Pneumologie et Oncologie Thoracique, AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France.<br /><searchLink fieldCode="AU" term="%22Makinson+A%22">Makinson A</searchLink>; INSERM U1175, Département de Maladies Infectieuses, Centre Hospitalier Universitaire de Montpellier, Université de Montpellier, Montpellier, France.<br /><searchLink fieldCode="AU" term="%22Zaegel-Faucher+O%22">Zaegel-Faucher O</searchLink>; Aix-Marseille Université, APHM Sainte-Marguerite, Service d'immuno-hématologie Clinique, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Greillier+L%22">Greillier L</searchLink>; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Soulie+C%22">Soulie C</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, laboratoire de virologie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Veyri+M%22">Veyri M</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département d'Oncologie Médicale, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bertheau+M%22">Bertheau M</searchLink>; Inserm-ANRS MIE, clinical research department, Paris, France.<br /><searchLink fieldCode="AU" term="%22Algarte+Genin+M%22">Algarte Genin M</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.<br /><searchLink fieldCode="AU" term="%22Gibowski+S%22">Gibowski S</searchLink>; Inserm-ANRS MIE, safety department, Paris, France.<br /><searchLink fieldCode="AU" term="%22Marcelin+AG%22">Marcelin AG</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, laboratoire de virologie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bihan+K%22">Bihan K</searchLink>; Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Baron+M%22">Baron M</searchLink>; Sorbonne University, Department of Medical Oncology Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.<br /><searchLink fieldCode="AU" term="%22Costagliola+D%22">Costagliola D</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.<br /><searchLink fieldCode="AU" term="%22Lambotte+O%22">Lambotte O</searchLink>; Département d'Immunologie Clinique, AP-HP, Hôpital Bicêtre, Université Paris-Saclay, Le Kremlin Bicêtre, France.<br /><searchLink fieldCode="AU" term="%22Spano+JP%22">Spano JP</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département d'Oncologie Médicale, Paris, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2024 Aug 22; Vol. 12 (8). <i>Date of Electronic Publication: </i>2024 Aug 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Observational Study; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39179255 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2024-009728 Languages: – Code: eng Text: English Titles: – TitleFull: Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Assoumou L – PersonEntity: Name: NameFull: Baldé R – PersonEntity: Name: NameFull: Katlama C – PersonEntity: Name: NameFull: Abbar B – PersonEntity: Name: NameFull: Delobel P – PersonEntity: Name: NameFull: Allegre T – PersonEntity: Name: NameFull: Lavole A – PersonEntity: Name: NameFull: Makinson A – PersonEntity: Name: NameFull: Zaegel-Faucher O – PersonEntity: Name: NameFull: Greillier L – PersonEntity: Name: NameFull: Soulie C – PersonEntity: Name: NameFull: Veyri M – PersonEntity: Name: NameFull: Bertheau M – PersonEntity: Name: NameFull: Algarte Genin M – PersonEntity: Name: NameFull: Gibowski S – PersonEntity: Name: NameFull: Marcelin AG – PersonEntity: Name: NameFull: Bihan K – PersonEntity: Name: NameFull: Baron M – PersonEntity: Name: NameFull: Costagliola D – PersonEntity: Name: NameFull: Lambotte O – PersonEntity: Name: NameFull: Spano JP IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 08 Text: 2024 Aug 22 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2051-1426 Numbering: – Type: volume Value: 12 – Type: issue Value: 8 Titles: – TitleFull: Journal for immunotherapy of cancer Type: main |
| ResultId | 1 |
